1
|
He Y, Rogasch JMM, Savic LJ. PET Imaging and Key Radiotracers for Evaluating Response to Locoregional Therapy in Hepatocellular Carcinoma. PET Clin 2025:S1556-8598(25)00024-0. [PMID: 40287367 DOI: 10.1016/j.cpet.2025.03.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2025]
Abstract
Locoregional therapies (LRTs) play a considerable role in the management of hepatocellular carcinoma (HCC), especially for patients who are not suitable for radical resection or transplantation. In clinical practice, assessment of LRTs is mainly based on computed tomography and MR imaging, but functional and metabolic information is less accessible. This article reviews the use of various the standardized uptake value parameters based on PET and multiple radiotracers for managing HCC after treatment with different LRTs, as well as parts of preclinical research. It discusses the current use of PET in more detail, as well as its advantages, disadvantages, and prospects.
Collapse
Affiliation(s)
- Yubei He
- Department of Radiology, Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Berlin 13353, Germany; Experimental and Clinical Research Center, A Joint Cooperation of Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Berlin 13125, Germany
| | - Julian M M Rogasch
- Department of Nuclear Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health at Charité, Universitätsmedizin Berlin, Berlin 10117, Germany
| | - Lynn Jeanette Savic
- Department of Radiology, Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Berlin 13353, Germany; Experimental and Clinical Research Center, A Joint Cooperation of Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Berlin 13125, Germany; Berlin Institute of Health at Charité, Universitätsmedizin Berlin, Berlin 10117, Germany.
| |
Collapse
|
2
|
Zhang W, Jiao Y, Zhang T, Liu X, Ye J, Zhang Y, Yang B, Dai M, Shi X, Fu F, Wang L, Xu C. Early detection of acute ischemic stroke using Contrast-enhanced electrical impedance tomography perfusion. Neuroimage Clin 2023; 39:103456. [PMID: 37379734 PMCID: PMC10318520 DOI: 10.1016/j.nicl.2023.103456] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2022] [Revised: 06/08/2023] [Accepted: 06/19/2023] [Indexed: 06/30/2023]
Abstract
A cerebral contrast-enhanced electrical impedance tomography perfusion method is developed for acute ischemic stroke during intravenous thrombolytic therapy. Several clinical contrast agents with stable impedance characteristics and high-conductivity contrast were screened experimentally as electrical impedance contrast agent candidates. The electrical impedance tomography perfusion method was tested on rabbits with focal cerebral infarction, and its capability for early detection was verified based on perfusion images. The experimental results showed that ioversol 350 performed significantly better as an electrical impedance contrast agent than other contrast agents (p < 0.01). Additionally, perfusion images of focal cerebral infarction in rabbits confirmed that the electrical impedance tomography perfusion method could accurately detect the location and area of different cerebral infarction lesions (p < 0.001). Therefore, the cerebral contrast-enhanced electrical impedance tomography perfusion method proposed herein combines traditional, dynamic continuous imaging with rapid detection and could be applied as an early, rapid-detection, auxiliary, bedside imaging method for patients after a suspected ischemic stroke in both prehospital and in-hospital settings.
Collapse
Affiliation(s)
- Weirui Zhang
- Department of Biomedical Engineering, Huazhong University of Science and Technology, Wuhan 430074, People's Republic of China; Department of Biomedical Engineering, the Fourth Military Medical University, Xi'an 710032, People's Republic of China; Shaanxi Key Laboratory for Bioelectromagnetic Detection and Intelligent Perception, Xi'an 710032, People's Republic of China
| | - Yang Jiao
- Department of Neurosurgery, Tangdu Hospital of Fourth Military Medical University, Xi'an 710032, People's Republic of China
| | - Tao Zhang
- Department of Biomedical Engineering, the Fourth Military Medical University, Xi'an 710032, People's Republic of China; Shaanxi Key Laboratory for Bioelectromagnetic Detection and Intelligent Perception, Xi'an 710032, People's Republic of China; Drug and Instrument Supervision and Inspection Station, Xining Joint Logistics Support Center, Lanzhou 730050, People's Republic of China
| | - Xuechao Liu
- Department of Biomedical Engineering, the Fourth Military Medical University, Xi'an 710032, People's Republic of China; Shaanxi Key Laboratory for Bioelectromagnetic Detection and Intelligent Perception, Xi'an 710032, People's Republic of China
| | - Jianan Ye
- Department of Biomedical Engineering, the Fourth Military Medical University, Xi'an 710032, People's Republic of China; Shaanxi Key Laboratory for Bioelectromagnetic Detection and Intelligent Perception, Xi'an 710032, People's Republic of China
| | - Yuyan Zhang
- Department of Biomedical Engineering, the Fourth Military Medical University, Xi'an 710032, People's Republic of China; Shaanxi Key Laboratory for Bioelectromagnetic Detection and Intelligent Perception, Xi'an 710032, People's Republic of China
| | - Bin Yang
- Department of Biomedical Engineering, the Fourth Military Medical University, Xi'an 710032, People's Republic of China; Shaanxi Key Laboratory for Bioelectromagnetic Detection and Intelligent Perception, Xi'an 710032, People's Republic of China
| | - Meng Dai
- Department of Biomedical Engineering, the Fourth Military Medical University, Xi'an 710032, People's Republic of China; Shaanxi Key Laboratory for Bioelectromagnetic Detection and Intelligent Perception, Xi'an 710032, People's Republic of China
| | - Xuetao Shi
- Department of Biomedical Engineering, the Fourth Military Medical University, Xi'an 710032, People's Republic of China; Shaanxi Key Laboratory for Bioelectromagnetic Detection and Intelligent Perception, Xi'an 710032, People's Republic of China
| | - Feng Fu
- Department of Biomedical Engineering, the Fourth Military Medical University, Xi'an 710032, People's Republic of China; Shaanxi Key Laboratory for Bioelectromagnetic Detection and Intelligent Perception, Xi'an 710032, People's Republic of China
| | - Liang Wang
- Department of Neurosurgery, Tangdu Hospital of Fourth Military Medical University, Xi'an 710032, People's Republic of China
| | - Canhua Xu
- Department of Biomedical Engineering, the Fourth Military Medical University, Xi'an 710032, People's Republic of China; Shaanxi Key Laboratory for Bioelectromagnetic Detection and Intelligent Perception, Xi'an 710032, People's Republic of China.
| |
Collapse
|
3
|
Yang T, Xiao H, Liu X, Wang Z, Zhang Q, Wei N, Guo X. Vascular Normalization: A New Window Opened for Cancer Therapies. Front Oncol 2021; 11:719836. [PMID: 34476218 PMCID: PMC8406857 DOI: 10.3389/fonc.2021.719836] [Citation(s) in RCA: 44] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2021] [Accepted: 07/23/2021] [Indexed: 12/17/2022] Open
Abstract
Preclinical and clinical antiangiogenic approaches, with multiple side effects such as resistance, have not been proved to be very successful in treating tumor blood vessels which are important targets for tumor therapy. Meanwhile, restoring aberrant tumor blood vessels, known as tumor vascular normalization, has been shown not only capable of reducing tumor invasion and metastasis but also of enhancing the effectiveness of chemotherapy, radiation therapy, and immunotherapy. In addition to the introduction of such methods of promoting tumor vascular normalization such as maintaining the balance between proangiogenic and antiangiogenic factors and targeting endothelial cell metabolism, microRNAs, and the extracellular matrix, the latest molecular mechanisms and the potential connections between them were primarily explored. In particular, the immunotherapy-induced normalization of blood vessels further promotes infiltration of immune effector cells, which in turn improves immunotherapy, thus forming an enhanced loop. Thus, immunotherapy in combination with antiangiogenic agents is recommended. Finally, we introduce the imaging technologies and serum markers, which can be used to determine the window for tumor vascular normalization.
Collapse
Affiliation(s)
- Ting Yang
- Department of General Surgery, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China
| | - Hongqi Xiao
- Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
| | - Xiaoxia Liu
- Department of General Surgery, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China
| | - Zhihui Wang
- Department of General Surgery, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China
| | - Qingbai Zhang
- Department of General Surgery, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China
| | - Nianjin Wei
- Department of General Surgery, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China
| | - Xinggang Guo
- Department of General Surgery, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China
| |
Collapse
|
4
|
Bashir U, Weeks A, Goda JS, Siddique M, Goh V, Cook GJ. Measurement of 18F-FDG PET tumor heterogeneity improves early assessment of response to bevacizumab compared with the standard size and uptake metrics in a colorectal cancer model. Nucl Med Commun 2019; 40:611-617. [PMID: 30893213 PMCID: PMC6553522 DOI: 10.1097/mnm.0000000000000992] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2018] [Accepted: 01/24/2019] [Indexed: 12/24/2022]
Abstract
PURPOSE Treatment of metastatic colorectal cancer frequently includes antiangiogenic agents such as bevacizumab. Size measurements are inadequate to assess treatment response to these agents, and newer response assessment criteria are needed. We aimed to evaluate F-FDG PET-derived texture parameters in a preclinical colorectal cancer model as alternative metrics of response to treatment with bevacizumab. MATERIALS AND METHODS Fourteen CD1 athymic mice injected in the flank with 5×106 LS174T cells (human colorectal carcinoma) were either untreated controls (n=7) or bevacizumab treated (n=7). After 2 weeks, mice underwent F-FDG PET/CT. Calliper-measured tumor growth (Δvol) and final tumor volume (Volcal), F-FDG PET metabolically active volume (Volmet), mean metabolism (Metmean), and maximum metabolism (Metmax) were measured. Twenty-four texture features were compared between treated and untreated mice. Immunohistochemical mean tumor vascular density was estimated by anti-CD-34 staining after tumor resection. RESULTS Treated mice had significantly lower tumor vascular density (P=0.032), confirming the antiangiogenic therapeutic effect of bevacizumab. None of the conventional measures were different between the two groups: Δvol (P=0.9), Volcal (P=0.7), Volmet (P=0.28), Metmax (P=0.7), or Metmean (P=0.32). One texture parameter, GLSZM-SZV (visually indicating that the F-FDG PET images of treated mice comprise uniformly sized clusters of different activity) had significantly different means between the two groups of mice (P=0.001). CONCLUSION F-FDG PET derived texture parameters, particularly GLSZM-SZV, may be valid biomarkers of tumor response to treatment with bevacizumab, before change in volume.
Collapse
Affiliation(s)
- Usman Bashir
- Department of Radiology, Barts and London NHS Trust
| | - Amanda Weeks
- Department of Cancer Imaging, School of Biomedical Engineering and Imaging Sciences
| | - Jayant S. Goda
- Department of Cancer Imaging, School of Biomedical Engineering and Imaging Sciences
| | - Muhammad Siddique
- Department of Cancer Imaging, School of Biomedical Engineering and Imaging Sciences
| | - Vicky Goh
- Department of Radiology, Barts and London NHS Trust
- Department of Radiology, Guy’s Hospital, London, UK
| | - Gary J. Cook
- Department of Radiology, Barts and London NHS Trust
- PET Imaging Centre and the Division of Imaging Sciences and Biomedical Engineering, King’s College London
| |
Collapse
|
5
|
Ueki A, Okuma T, Hamamoto S, Kageyama K, Murai K, Miki Y. Combination therapy involving radiofrequency ablation and targeted chemotherapy with bevacizumab plus paclitaxel and cisplatin in a rabbit VX2 lung tumor model. BMC Res Notes 2018; 11:251. [PMID: 29690935 PMCID: PMC5916726 DOI: 10.1186/s13104-018-3358-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2018] [Accepted: 04/18/2018] [Indexed: 11/12/2022] Open
Abstract
Objective Radiofrequency ablation (RFA) is less effective for large tumors > 3 cm in diameter. Various studies of combination therapy using RFA and other treatments have been conducted to improve the results of RFA treatment of lung tumors, survival was extended in a tumor model when RFA was followed by concomitant use of systemic chemotherapy. Bevacizumab (BCM) is a one of molecular target drugs. Numerous clinical trials and reports have shown BCM’s effect when used in combination with cisplatin (CDDP) in lung tumor. Our objective is to evaluate the survival of concurrent, combined use of radiofrequency ablation and BCM, and platinum-doublet chemotherapy [CDDP/paclitaxel (PTX)] in a rabbit VX2 lung tumor. Results Survival times of the RFA alone, CDDP/PTX, CDDP/PTX/BCM, RFA/CDDP/PTX, and RFA/CDDP/PTX/BCM groups were significantly prolonged compared to that of the control group (P = 0.0055, P = 0.0055, P = 0.0004, P = 0.0002, P = 0.0019, respectively). Survival of the RFA/CDDP/PTX/BCM group was not significantly prolonged compared to the RFA alone (P = 0.53) and CDDP/PTX/BCM group (P = 0.68), while showing a significantly shorter survival time than that of the RFA/CDDP/PTX group (P = 0.017). The addition to BCM with combination RFA and systemic therapy with CDDP/PTX did not have a positive effect on survival.
Collapse
Affiliation(s)
- Ai Ueki
- Department of Diagnostic and Interventional Radiology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.
| | - Tomohisa Okuma
- Department of Diagnostic and Interventional Radiology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan
| | - Shinichi Hamamoto
- Department of Diagnostic and Interventional Radiology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan
| | - Ken Kageyama
- Department of Diagnostic and Interventional Radiology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan
| | - Kazuki Murai
- Department of Diagnostic and Interventional Radiology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan
| | - Yukio Miki
- Department of Diagnostic and Interventional Radiology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan
| |
Collapse
|
6
|
Ursino S, Faggioni L, Guidoccio F, Ferrazza P, Seccia V, Neri E, Cernusco LN, Delishaj D, Morganti R, Volterrani D, Paiar F, Caramella D. Role of perfusion CT in the evaluation of functional primary tumour response after radiochemotherapy in head and neck cancer: preliminary findings. Br J Radiol 2016; 89:20151070. [PMID: 27377172 DOI: 10.1259/bjr.20151070] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
OBJECTIVE To report the initial results of a prospective study aimed at evaluating the CT perfusion parameter changes (∆PCTp) of the primary tumour after radiochemotherapy (RCT) in head and neck cancer (HNC) and to correlate with positron emission tomography (PET)/CT response. METHODS Eligibility criteria included HNC (Stage III-IV) candidates for RCT. Patients underwent perfusion CT (PCT) at baseline and at 3 weeks and 3 months after treatment. Blood volume, blood flow, mean transit time (MTT) and permeability surface (PS) product were computed. Moreover, PET/CT was performed at baseline and 3 months after treatment. The ∆PCTp were evaluated between baseline and 3-week/3-month evaluations, whereas PET/CT response was based on the maximum standardized uptake value changes according to the European Organization for Research and Treatment of Cancer criteria. RESULTS Between July 2012 and July 2015, 25 patients were enrolled. A significant reduction of all CT tumour perfusion parameters (PCTp) was observed from the baseline to after RCT (p < 0.001). Specifically, a significant reduction was shown at 3 weeks for all PCTp except MTT (from 6.18 to 5.14 s; p = 0.722). Differently, a significant reduction of all PCTp (p < 0.001) including MTT (from 6.18 to 2.24 s; p = 0.001) was shown at 3 months. Moreover, the reduction of PS resulted in a significant prediction of PET/CT response at 3 months (p = 0.037) with the trend also at 3 weeks (p = 0.099) at the multivariate analysis. CONCLUSION Our preliminary findings seem to show that almost all PCTp are significantly reduced after RCT, whereas PS seems to come out as the strongest factor in predicting the PET/CT response. ADVANCES IN KNOWLEDGE This article provides information on the potential useful role of PCT in evaluating tumour response after both early and late RCT.
Collapse
Affiliation(s)
- Stefano Ursino
- 1 Department of Radiation Oncology, University Hospital S. Chiara, Pisa, Italy
| | - Lorenzo Faggioni
- 2 Department of Radiology, University Hospital Cisanello, Pisa, Italy
| | - Federica Guidoccio
- 3 Department of Nuclear Medicine, University Hospital S.Chiara, Pisa, Italy
| | - Patrizia Ferrazza
- 1 Department of Radiation Oncology, University Hospital S. Chiara, Pisa, Italy
| | - Veronica Seccia
- 4 First Otorhinolaryngology Unit, University Hospital Cisanello, Pisa, Italy
| | - Emanuele Neri
- 2 Department of Radiology, University Hospital Cisanello, Pisa, Italy
| | - Luna N Cernusco
- 1 Department of Radiation Oncology, University Hospital S. Chiara, Pisa, Italy
| | - Durim Delishaj
- 1 Department of Radiation Oncology, University Hospital S. Chiara, Pisa, Italy
| | - Riccardo Morganti
- 5 Biostatistical Consulting, Department of Oncology, University Hospital S.Chiara, Pisa, Italy
| | - Duccio Volterrani
- 3 Department of Nuclear Medicine, University Hospital S.Chiara, Pisa, Italy
| | - Fabiola Paiar
- 1 Department of Radiation Oncology, University Hospital S. Chiara, Pisa, Italy
| | - Davide Caramella
- 2 Department of Radiology, University Hospital Cisanello, Pisa, Italy
| |
Collapse
|
7
|
A Novel Restraining Device for Small Animal Imaging Exams: Validation in Rabbits. BIOMED RESEARCH INTERNATIONAL 2015; 2015:571729. [PMID: 26114109 PMCID: PMC4465649 DOI: 10.1155/2015/571729] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/27/2015] [Accepted: 05/11/2015] [Indexed: 11/24/2022]
Abstract
Objective. To develop, validate, and patent a Restraining Device for Small Animal Imaging Exams (RDSAIE) that allows exams to be comfortably conducted without risks to animals and professionals. Methods. A RDSAIE with a mobile cover and shelf was built with transparent acrylic material. A total of six anesthetized rabbits were used to perform the following imaging exams of the skull: Cone Beam Computed Tomography, Magnetic Resonance Imaging, and Scintigraphy. Results. The device showed great functionality and full visibility of the animal behavior, which remained fully stabilized and immobilized in either the horizontal or vertical position without the need for a person to remain in the test room to assist them. The procedures were performed without difficulty, and images of good resolution and without artifacts were obtained. Conclusion. The RDSAIE is comfortable, safe, efficient, and ergonomic. It allows the easy placement of animals in different body positions, including the vertical, the maintenance of postural stability, and full visibility. It may be constructed for animals heavier than 4 kg and it is adaptable for translational studies in anima nobile.
Collapse
|
8
|
Kettner MA, Klapötke TM, Witkowski TG, von Hundling F. Synthesis, Characterisation and Crystal Structures of Two Bi-oxadiazole Derivatives Featuring the Trifluoromethyl Group. Chemistry 2015; 21:4238-41. [DOI: 10.1002/chem.201406436] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2014] [Indexed: 11/07/2022]
|